Metabolic profiling of attached and detached metformin and 2-deoxy-D-glucose treated breast cancer cells reveals adaptive changes in metabolome of detached cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 11 2021
Historique:
received: 01 04 2021
accepted: 06 09 2021
entrez: 2 11 2021
pubmed: 3 11 2021
medline: 21 1 2022
Statut: epublish

Résumé

Anchorage-independent growth of cancer cells in vitro is correlated to metastasis formation in vivo. Metformin use is associated with decreased breast cancer incidence and currently evaluated in cancer clinical trials. The combined treatment with metformin and 2-deoxy-D-glucose (2DG) in vitro induces detachment of viable MDA-MB-231 breast cancer cells that retain their proliferation capacity. This might be important for cell detachment from primary tumors, but the metabolic changes involved are unknown. We performed LC/MS metabolic profiling on separated attached and detached MDA-MB-231 cells treated with metformin and/or 2DG. High 2DG and metformin plus 2DG altered the metabolic profile similarly to metformin, inferring that metabolic changes are necessary but not sufficient while the specific effects of 2DG are crucial for detachment. Detached cells had higher NADPH levels and lower fatty acids and glutamine levels compared to attached cells, supporting the role of AMPK activation and reductive carboxylation in supporting anchorage-independent survival. Surprisingly, the metabolic profile of detached cells was closer to untreated control cells than attached treated cells, suggesting detachment might help cells adapt to energy stress. Metformin treated cells had higher fatty and amino acid levels with lower purine nucleotide levels, which is relevant for understanding the anticancer mechanisms of metformin.

Identifiants

pubmed: 34725457
doi: 10.1038/s41598-021-98642-0
pii: 10.1038/s41598-021-98642-0
pmc: PMC8560930
doi:

Substances chimiques

Hypoglycemic Agents 0
Metformin 9100L32L2N
Deoxyglucose 9G2MP84A8W

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21354

Subventions

Organisme : Slovenian Research Agency
ID : P1-0055
Organisme : Slovenian Research Agency
ID : P3-0067
Organisme : Slovenian Research Agency
ID : P1-0055
Organisme : Slovenian Research Agency
ID : P3-0067
Organisme : Slovenian Research Agency
ID : P1-0055
Organisme : Ministry of Education, Science and Sport of the Republic of Slovenia
ID : C3330-19-952026
Organisme : Ministry of Education, Science and Sport of the Republic of Slovenia
ID : C3330-19-952026

Informations de copyright

© 2021. The Author(s).

Références

Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230 doi: 10.1016/j.cell.2011.02.013
VanderHeiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
doi: 10.1126/science.1160809
Vander Heiden, M. G. & DeBerardinis, R. J. Understanding the intersections between metabolism and cancer biology. Cell 168, 657–669 (2017).
pubmed: 28187287 doi: 10.1016/j.cell.2016.12.039
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S. & Meier, C. R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33, 1304–1308 (2010).
pubmed: 20299480 pmcid: 2875444 doi: 10.2337/dc09-1791
Chae, Y. K. et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 7, 40767–40780 (2016).
pubmed: 27004404 pmcid: 5130043 doi: 10.18632/oncotarget.8194
Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3, e0242 (2014).
doi: 10.7554/eLife.02242
Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966 (2014).
pubmed: 25456737 doi: 10.1016/j.cmet.2014.09.018
Griss, T. et al. Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. PLoS Biol. 13, 1002309 (2015).
doi: 10.1371/journal.pbio.1002309
Zhao, B. et al. Anticancer mechanisms of metformin: a review of the current evidence. Life Sci. 254, 117717 (2020).
pubmed: 32339541 doi: 10.1016/j.lfs.2020.117717
Wokoun, U., Hellriegel, M., Emons, G. & Gründker, C. Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors. Oncol. Rep. 37, 2418–2424 (2017).
pubmed: 28350075 doi: 10.3892/or.2017.5491
Ben Sahra, I., Tanti, J.-F. & Bost, F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 6, 670–671 (2010).
pubmed: 28157435 doi: 10.4161/auto.6.5.12434
Cheong, J.-H. et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 10, 2350–2362 (2011).
pubmed: 21992792 pmcid: 3237863 doi: 10.1158/1535-7163.MCT-11-0497
Shafaee, A. et al. Induction of apoptosis by a combination of 2-deoxyglucose and metformin in esophageal squamous cell carcinoma by targeting cancer cell metabolism. Iran. J. Med. Sci. 44, 99–107 (2019).
pubmed: 30936596
Bizjak, M. et al. Combined treatment with metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro. Sci. Rep. 7, 1761 (2017).
pubmed: 28496098 pmcid: 5431940 doi: 10.1038/s41598-017-01801-5
Fidler, I. J. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 3, 453 (2003).
pubmed: 12778135 doi: 10.1038/nrc1098
Fidler, I. J. & Kripke, M. L. The challenge of targeting metastasis. Cancer Metastasis Rev. 34, 635–641 (2015).
pubmed: 26328524 pmcid: 4661188 doi: 10.1007/s10555-015-9586-9
Mori, S. et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28, 2796–2805 (2009).
pubmed: 19483725 pmcid: 3008357 doi: 10.1038/onc.2009.139
Buchheit, C. L., Rayavarapu, R. R. & Schafer, Z. T. The regulation of cancer cell death and metabolism by extracellular matrix attachment. Semin. Cell Dev. Biol. 23, 402–411 (2012).
pubmed: 22579674 doi: 10.1016/j.semcdb.2012.04.007
Jin, X. et al. A metastasis map of human cancer cell lines. Nature 588, 331–336 (2020).
pubmed: 33299191 pmcid: 8439149 doi: 10.1038/s41586-020-2969-2
Cailleau, R., Young, R., Olivé, M. & Reeves, W. J. Breast tumor cell lines from pleural effusions. JNCI J. Natl. Cancer Inst. 53, 661–674 (1974).
pubmed: 4412247 doi: 10.1093/jnci/53.3.661
Kaushik, A. K. & DeBerardinis, R. J. Applications of metabolomics to study cancer metabolism. Biochim. Biophys. Acta Rev. Cancer 1870, 2–14 (2018).
pubmed: 29702206 pmcid: 6193562 doi: 10.1016/j.bbcan.2018.04.009
Corominas-Faja, B. et al. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging 4, 480–498 (2012).
pubmed: 22837425 pmcid: 3433934 doi: 10.18632/aging.100472
Lord, S. R. et al. Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer. Cell Metab. 28, 679-688.e4 (2018).
pubmed: 30244975 pmcid: 6224605 doi: 10.1016/j.cmet.2018.08.021
Yan, M. et al. Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα. Metabolism 91, 18–29 (2019).
pubmed: 30468782 doi: 10.1016/j.metabol.2018.11.010
Liu, X., Romero, I. L., Litchfield, L. M., Lengyel, E. & Locasale, J. W. Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab. 24, 728–739 (2016).
pubmed: 27746051 pmcid: 5889952 doi: 10.1016/j.cmet.2016.09.005
Hodeib, M. et al. Metformin induces distinct bioenergetic and metabolic profiles in sensitive versus resistant high grade serous ovarian cancer and normal fallopian tube secretory epithelial cells. Oncotarget 9, 4044–4060 (2017).
pubmed: 29423103 pmcid: 5790520 doi: 10.18632/oncotarget.23661
Zhang, J. et al. Nuclear magnetic resonance-based metabolomic analysis of the anticancer effect of metformin treatment on cholangiocarcinoma cells. Front. Oncol. 10, 2438 (2020).
doi: 10.3389/fonc.2020.570516
Lubet, R. A. et al. Comparison of effects of diet on mammary cancer: efficacy of various preventive agents and metabolomic changes of different diets and agents. Cancer Prev. Res. Phila. Pa 11, 831–840 (2018).
doi: 10.1158/1940-6207.CAPR-18-0116
Udhane, S. S. et al. Combined transcriptome and metabolome analyses of metformin effects reveal novel links between metabolic networks in steroidogenic systems. Sci. Rep. 7, 8652 (2017).
pubmed: 28819133 pmcid: 5561186 doi: 10.1038/s41598-017-09189-y
He, J. et al. Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration. Sci. Rep. 5, 17423 (2015).
pubmed: 26616174 pmcid: 4663508 doi: 10.1038/srep17423
Janzer, A. et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc. Natl. Acad. Sci. 111, 10574–10579 (2014).
pubmed: 25002509 pmcid: 4115496 doi: 10.1073/pnas.1409844111
Lord, S. R. et al. Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. Br. J. Cancer 122, 258–265 (2020).
pubmed: 31819193 doi: 10.1038/s41416-019-0665-5
Urakami, K., Zangiacomi, V., Yamaguchi, K. & Kusuhara, M. Impact of 2-deoxy-D-glucose on the target metabolome profile of a human endometrial cancer cell line. Biomed. Res. 34, 221–229 (2013).
pubmed: 24190234 doi: 10.2220/biomedres.34.221
Miwa, H. et al. Leukemia cells demonstrate a different metabolic perturbation provoked by 2-deoxyglucose. Oncol. Rep. 29, 2053–2057 (2013).
pubmed: 23440281 doi: 10.3892/or.2013.2299
Sandulache, V. C. et al. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117, 2926–2938 (2011).
pubmed: 21692052 doi: 10.1002/cncr.25868
Ahadova, A., Gebert, J., von Doeberitz, M., Kopitz, J.K. & Kloor, M. Dose-dependent effect of 2-deoxy-D-glucose on glycoprotein mannosylation in cancer cells. IUBMB Life 67, 218–226 (2015).
pubmed: 25854316 doi: 10.1002/iub.1364
Lee, N., Jang, W.-J., Seo, J. H., Lee, S. & Jeong, C.-H. 2-Deoxy-d-glucose-induced metabolic alteration in human oral squamous SCC15 cells: involvement of N-glycosylation of axl and met. Metabolites 9, 188 (2019).
pmcid: 6780519 doi: 10.3390/metabo9090188
Pietzke, M., Zasada, C., Mudrich, S. & Kempa, S. Decoding the dynamics of cellular metabolism and the action of 3-bromopyruvate and 2-deoxyglucose using pulsed stable isotope-resolved metabolomics. Cancer Metab. 2, 9 (2014).
pubmed: 25035808 pmcid: 4101711 doi: 10.1186/2049-3002-2-9
Schafer, Z. T. et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109–113 (2009).
pubmed: 19693011 pmcid: 2931797 doi: 10.1038/nature08268
Jiang, L. et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532, 255–258 (2016).
pubmed: 27049945 pmcid: 4860952 doi: 10.1038/nature17393
Shi, Z., Mirza, M., Wang, B., Kennedy, M. A. & Weber, G. F. Osteopontin-a alters glucose homeostasis in anchorage-independent breast cancer cells. Cancer Lett. 344, 47–53 (2014).
pubmed: 24157812 doi: 10.1016/j.canlet.2013.10.008
Wheeler, L. J. et al. Multi-omic approaches identify metabolic and autophagy regulators important in ovarian cancer dissemination. iScience 19, 474–491 (2019).
pubmed: 31437751 pmcid: 6710300 doi: 10.1016/j.isci.2019.07.049
D’Amato, N. C. et al. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 75, 4651–4664 (2015).
pubmed: 26363006 pmcid: 4631670 doi: 10.1158/0008-5472.CAN-15-2011
Wick, A. N., Drury, D. R., Nakada, H. I., Wolfe, J. B. & Grabowski, W. The technical assistance of B B and R localization of the primary metabolic block produced by 2-deoxyglucose. J. Biol. Chem. 224, 963–969 (1957).
pubmed: 13405925 doi: 10.1016/S0021-9258(18)64988-9
Nakada, H. I. & Wick, A. N. The effect of 2-deoxyglucose on the metabolism of glucose, fructose, and galactose by rat diaphragm. J. Biol. Chem. 222, 671–676 (1956).
pubmed: 13367035 doi: 10.1016/S0021-9258(20)89925-6
Tyszka-Czochara, M., Konieczny, P. & Majka, M. Caffeic acid expands anti-tumor effect of metformin in human metastatic cervical carcinoma HTB-34 cells: implications of AMPK activation and impairment of fatty acids de novo biosynthesis. Int. J. Mol. Sci. 18, 462 (2017).
pmcid: 5343995 doi: 10.3390/ijms18020462
Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385–388 (2011).
pubmed: 22101431 pmcid: 3262117 doi: 10.1038/nature10642
Saladini, S. et al. Metformin impairs glutamine metabolism and autophagy in tumour cells. Cells 8, 49 (2019).
pmcid: 6356289 doi: 10.3390/cells8010049
Fendt, S.-M. et al. Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells. Nat. Commun. 4, 1–11 (2013).
doi: 10.1038/ncomms3236
Sullivan, L. B. et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162, 552–563 (2015).
pubmed: 26232225 pmcid: 4522278 doi: 10.1016/j.cell.2015.07.017
Rajh, M., Dolinar, K., Miš, K., Pavlin, M. & Pirkmajer, S. Medium renewal blocks anti-proliferative effects of metformin in cultured MDA-MB-231 breast cancer cells. PLoS ONE 11, e0154747 (2016).
pubmed: 27135408 pmcid: 4852933 doi: 10.1371/journal.pone.0154747
Kurtoglu, M. et al. Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther. 6, 3049–3058 (2007).
pubmed: 18025288 doi: 10.1158/1535-7163.MCT-07-0310
Ishino, K. et al. 2-Deoxy-d-glucose increases GFAT1 phosphorylation resulting in endoplasmic reticulum-related apoptosis via disruption of protein N-glycosylation in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 501, 668–673 (2018).
pubmed: 29753740 doi: 10.1016/j.bbrc.2018.05.041
Leung, H. J. et al. Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi’s sarcoma-associated herpesvirus replication and gene expression. Antimicrob. Agents Chemother. 56, 5794–5803 (2012).
pubmed: 22926574 pmcid: 3486618 doi: 10.1128/AAC.01126-12
Labuschagne, C. F., Cheung, E. C., Blagih, J., Domart, M.-C. & Vousden, K. H. Cell clustering promotes a metabolic switch that supports metastatic colonization. Cell Metab. 30, 720-734.e5 (2019).
pubmed: 31447323 pmcid: 6863392 doi: 10.1016/j.cmet.2019.07.014
Sundararaman, A., Amirtham, U. & Rangarajan, A. Calcium-oxidant signaling network regulates AMP-activated protein kinase (AMPK) activation upon matrix deprivation. J. Biol. Chem. 291, 14410–14429 (2016).
pubmed: 27226623 pmcid: 4938166 doi: 10.1074/jbc.M116.731257
Bueno, M. J. et al. Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. Nat. Commun. 10, 5011 (2019).
pubmed: 31676791 pmcid: 6825217 doi: 10.1038/s41467-019-13028-1
McGuirk, S. et al. PGC-1α supports glutamine metabolism in breast cancer. Cancer Metab. 1, 22 (2013).
pubmed: 24304688 pmcid: 4178216 doi: 10.1186/2049-3002-1-22
Sedano, J. M. et al. Hypoxanthine phosphoribosyl transferase 1 is upregulated, predicts clinical outcome and controls gene expression in breast cancer. Cancers 12, 1522 (2020).
doi: 10.3390/cancers12061522
Luca, A. D. et al. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget 6, 14777–14795 (2015).
pubmed: 26087310 pmcid: 4558115 doi: 10.18632/oncotarget.4401
Sancho, P. et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 22, 590–605 (2015).
pubmed: 26365176 doi: 10.1016/j.cmet.2015.08.015
Bordag, N. et al. Fast filtration of bacterial or mammalian suspension cell cultures for optimal metabolomics results. PLoS ONE 11, e01559389 (2016).
doi: 10.1371/journal.pone.0159389
Vogel, F. C. E. et al. Targeting the H3K4 Demethylase KDM5B reprograms the metabolome and phenotype of melanoma cells. J. Invest. Dermatol. 139, 2506-2516.e10 (2019).
pubmed: 31229500 doi: 10.1016/j.jid.2019.06.124
Buescher, J. M., Moco, S., Sauer, U. & Zamboni, N. Ultrahigh performance liquid chromatography−tandem mass spectrometry method for fast and robust quantification of anionic and aromatic metabolites. Anal. Chem. 82, 4403–4412 (2010).
pubmed: 20433152 doi: 10.1021/ac100101d
Trausinger, G. et al. Identification of novel metabolic interactions controlling carbon flux from xylose to ethanol in natural and recombinant yeasts. Biotechnol. Biofuels 8, 157 (2015).
pubmed: 26413156 pmcid: 4582818 doi: 10.1186/s13068-015-0340-x
Chambers, M. C. et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol. 30, 918–920 (2012).
pubmed: 23051804 pmcid: 3471674 doi: 10.1038/nbt.2377
Fröhlich, E. E. et al. Cognitive impairment by antibiotic-induced gut dysbiosis: analysis of gut microbiota-brain communication. Brain. Behav. Immun. 56, 140–155 (2016).
pubmed: 26923630 pmcid: 5014122 doi: 10.1016/j.bbi.2016.02.020
Mueller, K. M. et al. Adipocyte glucocorticoid receptor deficiency attenuates aging- and HFD-induced obesity and impairs the feeding-fasting transition. Diabetes 66, 272–286 (2017).
pubmed: 27650854 doi: 10.2337/db16-0381
Wishart, D. S. et al. HMDB 4.0 the human metabolome database for 2018. Nucleic Acids Res. 46, D608–D617 (2018).
pubmed: 29140435 doi: 10.1093/nar/gkx1089

Auteurs

Jernej Repas (J)

Institute of Biophysics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Elmar Zügner (E)

Joanneum Research Health - Institute for Biomedicine and Health Sciences, Graz, Austria.

Boris Gole (B)

Center for Human Molecular Genetics and Pharmacogenomics, Medical Faculty, University of Maribor, Maribor, Slovenia.

Maruša Bizjak (M)

Institute of Biophysics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Group for Nano- and Biotechnological Applications, Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, Slovenia.
Pharmacy Institute, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.

Uroš Potočnik (U)

Center for Human Molecular Genetics and Pharmacogenomics, Medical Faculty, University of Maribor, Maribor, Slovenia.
Laboratory for Biochemistry, Molecular biology and Genomics, Faculty for Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenia.

Christoph Magnes (C)

Joanneum Research Health - Institute for Biomedicine and Health Sciences, Graz, Austria. christoph.magnes@joanneum.at.

Mojca Pavlin (M)

Institute of Biophysics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. mojca.pavlin@mf.uni-lj.si.
Group for Nano- and Biotechnological Applications, Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, Slovenia. mojca.pavlin@mf.uni-lj.si.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH